No Data
Harbin Medisan Pharmaceutical (002900.SZ): Received a total of 25.5098 million yuan in government subsidies.
Gelonghui, on November 18, announced that Harbin Medisan Pharmaceutical (002900.SZ) disclosed that its wholly-owned subsidiaries, Lanxi Harbin Medisan Pharmaceutical Co., Ltd. (hereinafter referred to as "Lanxi Pharmaceutical"), Guangzhou Harbin Medisan Biotechnology Co., Ltd. (hereinafter referred to as "Guangzhou Harbin Medisan"), Lanxi Harbin Medisan Medicine Co., Ltd. (hereinafter referred to as "Lanxi Medicine"), Harbin Sanlian Lide Biotechnology Co., Ltd. (hereinafter referred to as "Lide Biotechnology"), Lingbao Harbin Medisan Biopharmaceutical Co., Ltd. (hereinafter referred to as "Lingbao Harbin Medisan"), and Peking Harbin Medisan Technology Co., Ltd. (hereinafter referred to as "Peking Technology") will be active from February 4, 2024 to...
There Might Be More To Harbin Medisan Pharmaceutical's (SZSE:002900) Story Than Just Weak Earnings
Harbin Medisan Pharmaceutical (002900.SZ): The pharmaceutical sodium bicarbonate injection has passed the consistency evaluation.
On October 28th, Harbin Medisan Pharmaceutical (002900.SZ) announced that the company recently received the drug supplementary application approval notice issued by the National Medical Products Administration. The company's pharmaceutical Sodium Bicarbonate Injection passed the generic drug quality and efficacy consistency evaluation (referred to as "consistency evaluation"). Sodium Bicarbonate Injection is mainly used to treat metabolic acidosis, alkalinize urine, and intravenous infusion has a nonspecific therapeutic effect on certain drug intoxications.
Kazakh Triptych: Report for the third quarter of 2024
Harbin Medisan Pharmaceutical (002900.SZ): The net income in the first three quarters was 40.5828 million yuan, a decrease of 32.50% year-on-year.
Gelonghui, October 24th | Harbin Medisan Pharmaceutical (002900.SZ) released its third quarter report, achieving revenue of 0.839 billion yuan in the first three quarters, a decrease of 9.10% year-on-year; net income attributable to shareholders of the listed company was 40.5828 million yuan, a decrease of 32.50% year-on-year; net income after deducting non-recurring gains and losses was 33.1014 million yuan, an increase of 3.44% year-on-year; basic earnings per share was 0.13 yuan/share.
Harbin Medisan Pharmaceutical (002900.SZ) released its performance for the first three quarters, with a net income of 40.5828 million yuan, a year-on-year decrease of 32.50%.
Harbin Medisan Pharmaceutical (002900.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue of 8...
No Data
No Data